{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:02:50Z","timestamp":1761541370527,"version":"build-2065373602"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":2012,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1111\/jth.13659","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T16:12:40Z","timestamp":1487693560000},"page":"848-857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long\u2010term treatment of cancer\u2010associated thrombosis: the choice of the optimal anticoagulant"],"prefix":"10.1016","volume":"15","author":[{"given":"I.","family":"Elalamy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Ageno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13659_bb0010","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3747\/co.21.1864","article-title":"Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management","volume":"21","author":"Donnellan","year":"2014","journal-title":"Curr Oncol"},{"issue":"Suppl. 6","key":"10.1111\/jth.13659_bb0015","doi-asserted-by":"crossref","first-page":"vi85","DOI":"10.1093\/annonc\/mdr392","article-title":"Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines","volume":"22","author":"Mandala","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1111\/jth.13659_bb0020","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.13659_bb0025","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.6004\/jnccn.2013.0163","article-title":"National comprehensive cancer n. Venous thromboembolic disease","volume":"11","author":"Streiff","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1111\/jth.13659_bb0030","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"Lyman","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.13659_bb0035","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","article-title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"17","author":"Farge","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1111\/jth.13659_bb0040","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1200\/JOP.2015.004473","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"11","author":"Lyman","year":"2015","journal-title":"J Oncol Pract"},{"key":"10.1111\/jth.13659_bb0045","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.thromres.2012.08.290","article-title":"Long\u2010term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta\u2010analysis of 5 randomized trials in non\u2010cancer and cancer patients","volume":"130","author":"Laporte","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13659_bb0050","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.thromres.2008.09.002","article-title":"Efficacy of low\u2010 molecular\u2010 weight\u2010 heparin versus vitamin K antagonists for long term treatment of cancer\u2010associated venous thromboembolism in adults: a systematic review of randomized controlled trials","volume":"123","author":"Louzada","year":"2009","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13659_bb0055","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: a network meta\u2010analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"Posch","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13659_bb0060","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.11458","article-title":"Clinical characteristics and management of cancer\u2010associated acute venous thromboembolism: findings from the MASTER Registry","volume":"93","author":"Imberti","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/jth.13659_bb0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1160\/TH10-08-0506","article-title":"Inconsistencies in the planning of the duration of anticoagulation among outpatients with acute deep\u2010vein thrombosis. Results from the OTIS\u2010DVT Registry","volume":"105","author":"Spirk","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13659_bb0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11239-015-1313-4","article-title":"Guidance for the prevention and treatment of cancer\u2010associated venous thromboembolism","volume":"41","author":"Khorana","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.13659_bb0075","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1111\/jth.13659_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic thromboembolism in patients with cancer (EINSTEIN\u2010DVT and EINSTEIN\u2010PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.13659_bb0085","doi-asserted-by":"crossref","first-page":"e000091","DOI":"10.1136\/esmoopen-2016-000091","article-title":"Renal insufficiency and cancer treatments","volume":"1","author":"Launay\u2010Vacher","year":"2016","journal-title":"ESMO Open"},{"key":"10.1111\/jth.13659_bb0090","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3324\/haematol.13055","article-title":"Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry","volume":"93","author":"Prandoni","year":"2008","journal-title":"Haematologica"},{"key":"10.1111\/jth.13659_bb0095","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.amjmed.2006.04.028","article-title":"Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry","volume":"119","author":"Monreal","year":"2006","journal-title":"Am J Med"},{"key":"10.1111\/jth.13659_bb0100","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/jth.12411","article-title":"Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer\u2010associated venous thromboembolism during anticoagulant treatment","volume":"11","author":"Kooiman","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13659_bb0105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"issue":"Suppl. 2","key":"10.1111\/jth.13659_bb0110","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0049-3848(10)70015-3","article-title":"Bleeding complications associated with anticoagulant therapy in patients with cancer","volume":"125","author":"Trujillo\u2010Santos","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13659_bb0115","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V122.21.2310.2310","article-title":"Treatment of cancer\u2010associated thrombosis","volume":"122","author":"Lee","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.13659_bb0120","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low\u2010molecular\u2010weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.13659_bb0125","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180\u2010day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/jth.13659_bb0130","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13659_bb0135","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long\u2010term low\u2010molecular\u2010weight heparin versus usual care in proximal\u2010vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"key":"10.1111\/jth.13659_bb0140","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ejvs.2008.11.030","article-title":"A randomised open\u2010label trial comparing long\u2010term sub\u2010cutaneous low\u2010molecular\u2010weight heparin compared with oral\u2010anticoagulant therapy in the treatment of deep venous thrombosis","volume":"37","author":"Romera","year":"2009","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1111\/jth.13659_bb0145","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood.V124.21.LBA-2.LBA-2","article-title":"A randomized trial of long\u2010term tinzaparin, a Low\u2010Molecular\u2010Weight Heparin (LMWH), versus warfarin for treatment of acute Venous Thromboembolism (VTE) in cancer patients \u2010 the CATCH Study","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.13659_bb0150","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13659_bb0155","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2013.51.7433","article-title":"Optimal duration of low molecular weight heparin for the treatment of cancer\u2010related deep vein thrombosis: the Cancer\u2010DACUS Study","volume":"32","author":"Napolitano","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.13659_bb0160","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.chest.2015.10.069","article-title":"Cohort study on the management of cancer\u2010associated venous thromboembolism aimed at the safety of stopping anticoagulant therapy in patients cured of cancer","volume":"149","author":"van der Hulle","year":"2016","journal-title":"Chest"},{"key":"10.1111\/jth.13659_bb0165","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1538-7836.2012.04693.x","article-title":"A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer","volume":"10","author":"Levine","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13659_bb0170","first-page":"391","article-title":"Direct oral anticoagulants for the treatment of unprovoked venous thromboembolism: a meta\u2010analysis of randomised controlled trials","volume":"13","author":"Di Minno","year":"2015","journal-title":"Blood Transfus"},{"key":"10.1111\/jth.13659_bb0175","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer a network meta\u2010analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"Posch","year":"2015","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13659_bb0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1378\/chest.14-0402","article-title":"Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta\u2010analysis","volume":"147","author":"Vedovati","year":"2015","journal-title":"Chest"},{"key":"10.1111\/jth.13659_bb0185","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.13659_bb0190","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer\u2010associated thrombosis: a systematic review and meta\u2010analysis","volume":"134","author":"Carrier","year":"2014","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13659_bb0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3747\/co.22.2392","article-title":"Clinical challenges in patients with cancer\u2010associated thrombosis: Canadian expert consensus recommendations","volume":"22","author":"Carrier","year":"2015","journal-title":"Curr Oncol"},{"key":"10.1111\/jth.13659_bb0200","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2162-3619-2-21","article-title":"Tinzaparin and other low\u2010molecular\u2010weight heparins: what is the evidence for differential dependence on renal clearance?","volume":"2","author":"Johansen","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"10.1111\/jth.13659_bb0205","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00002018-200225100-00005","article-title":"Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients","volume":"25","author":"Pautas","year":"2002","journal-title":"Drug Saf"},{"key":"10.1111\/jth.13659_bb0210","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/j.1538-7836.2011.04458.x","article-title":"No accumulation of the peak anti\u2010factor Xa activity of tinzaparin in elderly patients with moderate\u2010to\u2010severe renal impairment: the IRIS substudy","volume":"9","author":"Siguret","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13659_bb0215","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1160\/TH06-09-0513","article-title":"Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study","volume":"97","author":"Mahe","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13659_bb0220","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1016\/j.lpm.2014.03.032","article-title":"[Prospective study of drug\u2010induced allergic nephropathy in eleven French nephrology units.]","volume":"43","author":"Leven","year":"2014","journal-title":"Presse Med"},{"key":"10.1111\/jth.13659_bb0225","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jth.13659_bb0230","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2165\/00003495-200868120-00007","article-title":"Dabigatran etexilate","volume":"68","author":"Sanford","year":"2008","journal-title":"Drugs"},{"key":"10.1111\/jth.13659_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/jth.13659_bb0240","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","article-title":"Rivaroxaban: a new oral factor Xa inhibitor","volume":"30","author":"Perzborn","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/jth.13659_bb0245","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59\u20107939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. 2","key":"10.1111\/jth.13659_bb0250","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1016\/S0049-3848(14)50027-8","article-title":"Treatment of cancer\u2010associated thrombosis: perspectives on the use of novel oral anticoagulants","volume":"133","author":"Lee","year":"2014","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13659_bb0255","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/TCRM.S49063","article-title":"New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients","volume":"10","author":"Gerotziafas","year":"2014","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/jth.13659_bb0260","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13659_bb0265","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Investigators A\u2010. Andexanet Alfa for acute major bleeding associated with Factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13659_bb0270","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13659_bb0275","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.annfar.2013.04.016","article-title":"[Management of major bleeding complications and emergency surgery in patients on long\u2010term treatment with direct oral anticoagulants, thrombin or factor\u2010Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) \u2010 March 2013]","volume":"32","author":"Pernod","year":"2013","journal-title":"Ann Fr Anesth Reanim"},{"key":"10.1111\/jth.13659_bb0280","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00216-010-4220-8","article-title":"Protamine neutralisation of low molecular weight heparins and their oligosaccharide components","volume":"399","author":"Schroeder","year":"2011","journal-title":"Anal Bioanal Chem"},{"key":"10.1111\/jth.13659_bb0285","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.thromres.2011.07.017","article-title":"Physician and patient perceptions of the route of administration of venous thromboembolism prophylaxis: results from an international survey","volume":"129","author":"Cimminiello","year":"2012","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13659_bb0290","first-page":"453","article-title":"Cancer\u2010associated thrombosis, low\u2010molecular\u2010weight heparin, and the patient experience: a qualitative study","volume":"8","author":"Seaman","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1111\/jth.13659_bb0295","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1477-7525-7-30","article-title":"Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT\u2010Q)","volume":"7","author":"Prins","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1111\/jth.13659_bb0300","first-page":"1545","article-title":"Long\u2010term use of Low\u2010Molecular\u2010Weight Heparin (LMWH) for Cancer(Associated Venous Thromboembolism (VTE): adherence to recommendations in clinbical practice based on tropique, a prospective observational study","volume":"124","author":"Farge","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/jth.13659_bb0305","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1160\/TH08-12-0832","article-title":"Anti\u2010cancer properties of low\u2010molecular\u2010weight heparin: preclinical evidence","volume":"102","author":"Mousa","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13659_bb0310","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000175157","article-title":"Non\u2010anticoagulant heparins and inhibition of cancer","volume":"36","author":"Casu","year":"2008","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1111\/jth.13659_bb0315","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.patbio.2008.03.003","article-title":"Pathogenesis of venous thromboembolic disease in cancer","volume":"56","author":"Elalamy","year":"2008","journal-title":"Pathologie\u2010Biologie"},{"issue":"Suppl. 1","key":"10.1111\/jth.13659_bb0320","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/S0049-3848(16)30115-3","article-title":"The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH\/warfarin\/DOACs?","volume":"140","author":"Noble","year":"2016","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13659_bb0325","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"10.1111\/jth.13659_bb0330","first-page":"S","article-title":"Apixabanfor the treatment of venous thromboembolism in cancre patients: data from the Amplify trial","volume":"30","author":"Agnelli","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1111\/jth.13659_bb0335","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: results from a non\u2010inferiority subgroup analysis of the Hokusai\u2010VTE randomised, double\u2010blind, double\u2010dummy trial","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.13659_bb0340","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5045\/br.2014.49.2.77","article-title":"Direct oral anticoagulants in the treatment of cancer\u2010associated venous thromboembolism","volume":"49","author":"Yhim","year":"2014","journal-title":"Blood Research"},{"key":"10.1111\/jth.13659_bb0345","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/1471-2407-13-284","article-title":"CATCH: a randomised clinical trial comparing long\u2010term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients","volume":"13","author":"Lee","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1111\/jth.13659_bb0350","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN\u2010DVT and EINSTEIN\u2010PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.13659_bb0355","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1160\/TH15-06-0452","article-title":"Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE\u2010cancer study","volume":"114","author":"Van Es","year":"2015","journal-title":"Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13659","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622008844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622008844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13659\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:17:09Z","timestamp":1761535029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622008844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1538783622008844"],"URL":"https:\/\/doi.org\/10.1111\/jth.13659","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long\u2010term treatment of cancer\u2010associated thrombosis: the choice of the optimal anticoagulant","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}